Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Growth Failure Clear all
Completed Phase 3 Interventional

Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis

NCT00943995
View directory record Official record
Conditions
Kidney Failure, Chronic, Renal Dialysis
Interventions
somatropin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Ponsegromab in People With Heart Failure

NCT05492500
View directory record Official record
Conditions
Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 3 Interventional

Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome

NCT00190658
View directory record Official record
Conditions
Failure to Thrive
Interventions
Somatropin (rDNA origin) for injection
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
3 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2010 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional Results available

Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

NCT00395291
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease
Interventions
MK-0677, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Jul 21, 2026, 11:10 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib, Amivantamab, Pemetrexed, Carboplatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
28
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional

Growth Hormone Treatment of Children With HIV-Associated Growth Failure

NCT00006143
View directory record Official record
Conditions
HIV Infections
Interventions
Somatropin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 13 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 21, 2026, 11:10 AM EDT
Completed No phase listed Observational

The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation

NCT00056784
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

NCT00125164
View directory record Official record
Conditions
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Interventions
rhIGF-1 (mecasermin, Tercica, Inc.)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years to 12 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Home Weight Tele-monitoring on the Number of Office Visits in the First Six Weeks of Life in Infants.

NCT04985227
View directory record Official record
Conditions
Failure to Thrive, Newborn Morbidity
Interventions
Home weight monitoring
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting Phase 3 Interventional

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851
View directory record Official record
Conditions
Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Palo Alto, California • Sacramento, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed No phase listed Observational

National Cooperative Growth Study in CKD

NCT00616278
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
1 Day to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Obesity and Oral Contraceptive Failure

NCT01944306
View directory record Official record
Conditions
Contraception, Fetal Growth Retardation, Infant, Small for Gestational Age, Obesity
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Jul 21, 2026, 11:10 AM EDT
Completed No phase listed Observational

Evaluation of Patients With Unresolved Chromosome Abnormalities

NCT00001639
View directory record Official record
Conditions
Abnormalities, Failure to Thrive, Mental Retardation, Microcephaly
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting Not applicable Interventional

Targeted Fortification of Donor Breast Milk in Preterm Infants

NCT04294368
View directory record Official record
Conditions
Prematurity; Extreme, Failure to Thrive in Newborn, Growth Retardation, Growth Failure, Infant Nutrition Disorders
Interventions
Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid, Similac Liquid Protein Fortifier, Nestle Microlipid, Medica Nutrition SolCarb, Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification), Similac Liquid Protein Fortifier (Targeted Fortification), Nestle Microlipid (Targeted Fortification), Medica Nutrition SolCarb (Targeted Fortification), Analysis with Miris (AB) Human Milk Analyzer
Dietary Supplement · Other
Lead sponsor
Columbia University
Other
Eligibility
1 Day to 21 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Phase 4 Interventional

Effect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney Disease

NCT00194961
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Recombinant Human Growth Hormone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
6 Months to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Jul 21, 2026, 11:10 AM EDT
Not listed Phase 3 Interventional

Treatment of Children With Insufficient Secretion of Growth Hormone

NCT00271518
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
growth hormone (somatropin)
Drug
Lead sponsor
LG Life Sciences
Industry
Eligibility
3 Years to 11 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Iza-bren, Carboplatin, Cisplatin, Pemetrexed
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
28
States / cities
Irvine, California • Orange, California • Edwards, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional

Palliative Care Population Management Project for Integrated Care Management Program for High-Risk Patients

NCT02879357
View directory record Official record
Conditions
Failure to Thrive
Interventions
Training
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional

Randomized Study of Recombinant Human Growth Hormone in Patients on Chronic Hemodialysis or Peritoneal Dialysis

NCT00004429
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
growth hormone
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease

NCT00511329
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid, Crohn Disease
Interventions
somatropin [rDNA origin] for injection
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Not applicable Interventional

Mobile-Thrive - A Family Self-Management Approach to Failure to Thrive

NCT02589132
View directory record Official record
Conditions
Failure to Thrive
Interventions
Mobile-Thrive application
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Months to 4 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

NCT04393909
View directory record Official record
Conditions
Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions
Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Not applicable Interventional

Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia

NCT03532555
View directory record Official record
Conditions
Infant,Premature, Bronchopulmonary Dysplasia, Growth Failure
Interventions
Zinc Acetate, No supplemental zinc
Dietary Supplement · Other
Lead sponsor
University of Utah
Other
Eligibility
14 Days to 28 Days
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

NCT00490100
View directory record Official record
Conditions
Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
Interventions
Increlex
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 20 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Jul 21, 2026, 11:10 AM EDT